Company intelligence / Profile preview

BOB FoodTech

Ownership: Private
Development stage: Preclinical

Overview

BOB FoodTech has developed a patented RNA-based platform that enables the selective removal of metabolic toxins such as lactate and ammonia from cell culture media. This technology facilitates efficient media recycling, reduces production costs, and supports sustainable cultivated meat and seafood production. The company is at an early stage with pilot applications in cultivated protein industries. No clinical results apply.

Modalities: RNA-based technologyEncapsulated ribonucleic acid constructsBio Optimal Binding particles
Industry: Non-Drug Biotech

Partnerships

EIT Food Accelerator NetworkStartLife accelerator programThe Kitchen Hub incubator at Tel Aviv University

Beyond the preview

Go deeper on BOB FoodTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOB FoodTech.

Explore the full profile